Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2 …
…, A Chan, S Goel, K Catron, SC Chapman… - The Lancet …, 2020 - thelancet.com
Background Patients with HER2-positive breast cancer who have received two or more
previous therapies for advanced disease have few effective treatment options. The monarcHER …
previous therapies for advanced disease have few effective treatment options. The monarcHER …
A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor–positive breast cancer
…, P Conte, V Diéras, NU Lin, M Bear, SC Chapman… - Clinical Cancer …, 2020 - AACR
Purpose: The primary objective was to evaluate intracranial objective response rate (iORR)
in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to …
in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to …
[HTML][HTML] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
…, L Paz-Ares, MJ Chisamore, SC Chapman… - NPJ Breast …, 2022 - nature.com
This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated
the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in …
the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in …
Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study
…, DE Rathkopf, R Sanford, SC Chapman… - Clinical Cancer …, 2020 - AACR
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth,
and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) …
and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) …
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase …
Background Tumor-associated macrophages (TAMs) promote tumor growth, metastasis,
and therapeutic resistance via colony-stimulating factor-1 (CSF-1), acting through CSF-1 …
and therapeutic resistance via colony-stimulating factor-1 (CSF-1), acting through CSF-1 …
nextMONARCH: abemaciclib monotherapy or combined with tamoxifen for metastatic breast cancer
…, G Jerusalem, R Hegg, J Huober, SC Chapman… - Clinical breast …, 2021 - Elsevier
Background Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor administered
continuously for hormone receptor-positive (HR + ), human epidermal growth factor …
continuously for hormone receptor-positive (HR + ), human epidermal growth factor …
Aurora A–Selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells, and shows potent preclinical antitumor efficacy
…, K Boehnke, C Baquero, YH Hui, SC Chapman… - Molecular cancer …, 2019 - AACR
Although Aurora A, B, and C kinases share high sequence similarity, especially within the
kinase domain, they function distinctly in cell-cycle progression. Aurora A depletion primarily …
kinase domain, they function distinctly in cell-cycle progression. Aurora A depletion primarily …
[HTML][HTML] Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a phase 1b study
…, AM Manuel, A Lithio, GL Price, SC Chapman… - Frontiers in …, 2022 - frontiersin.org
Background: Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression
and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 …
and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 …
Abemaciclib does not have a clinically meaningful effect on pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 substrates in patients with cancer
PK Turner, SD Hall, SC Chapman, JL Rehmel… - Drug Metabolism and …, 2020 - ASPET
Abemaciclib is an orally administered, potent inhibitor of cyclin-dependent kinases 4 and 6
and is metabolized extensively by CYP3A4. The effects of abemaciclib on several CYPs were …
and is metabolized extensively by CYP3A4. The effects of abemaciclib on several CYPs were …
Opportunities for quantitative translational modeling in oncology
A 2‐day meeting was held by members of the UK Quantitative Systems Pharmacology Network
(< http://www.qsp‐uk.net/ >) in November 2018 on the topic of Translational Challenges …
(< http://www.qsp‐uk.net/ >) in November 2018 on the topic of Translational Challenges …